CEUS Evaluation of Hydrocephalus in Neonates and Infants

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
Hydrocephalus in InfantsHydrocephalus Acquired
Interventions
DRUG

Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]

Injection of Sulfur hexafluoride lipid-type A microspheres contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg before performing the contrast-enhanced ultrasound. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected.

Trial Locations (1)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
lead

Children's Hospital of Philadelphia

OTHER

NCT06693752 - CEUS Evaluation of Hydrocephalus in Neonates and Infants | Biotech Hunter | Biotech Hunter